Literature DB >> 8418039

Structural and serological specificities of Pasteurella haemolytica lipopolysaccharides.

R P Lacroix1, J R Duncan, R P Jenkins, R A Leitch, J A Perry, J C Richards.   

Abstract

Lipopolysaccharides (LPSs) from 16 serotypes of Pasteurella haemolytica were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and examined by silver staining and immunoblotting. Silver staining of proteinase K-digested cell lysates revealed two rough LPS serotypes (serotypes 2 and 8), which lacked demonstrable O-polysaccharide, while 14 others demonstrated a ladder pattern characteristic of smooth-type LPS. Purified LPSs from several serotypes yielded O-polysaccharide in addition to low-molecular-weight core oligosaccharide components when subjected to mild acid hydrolysis. Nuclear magnetic resonance spectroscopy revealed the O-chain polysaccharides of serotypes 1, 6, and 9 to be identical. Immunoblots using hyperimmune rabbit, mouse, bovine, and ovine sera from homologous and heterologous serotypes supported this finding and suggested that most of the A biotypes share common O-chain epitopes. Immunoblotting results also supported structural data which demonstrated that the O-polysaccharides of serotypes 3 and 15 and of serotypes 4 and 10 (T biotypes) are identical. Nuclear magnetic resonance analysis indicated that the core oligosaccharides of serotypes 1, 6, 8, 9, and 12 share similar structures, but that they are distinct from those of serotypes 3, 4, 10, and 15. Immunoblots with hyperimmune antisera and monoclonal antibody having specificity for the core region of serotype 1 LPS revealed shared epitopes in the core oligosaccharides of several A biotypes. Characterization of the molecular structure and antigenic specificities of LPS has been an important consideration in the development of purity and potency assays for veterinary vaccines which contain P. haemolytica.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8418039      PMCID: PMC302702          DOI: 10.1128/iai.61.1.170-181.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Colonial variation of Pasteurella haemolytica isolated from sheep.

Authors:  E L BIBERSTEIN; M E MEYER; P C KENNEDY
Journal:  J Bacteriol       Date:  1958-10       Impact factor: 3.490

2.  Characterisation of a new serotype of P haemolytica isolated in Hungary.

Authors:  L Fodor; J Varga; J Hajtós; W Donachie; N J Gilmour
Journal:  Res Vet Sci       Date:  1988-05       Impact factor: 2.534

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Rapid plate agglutination procedure for serotyping Pasteurella haemolytica.

Authors:  G H Frank; G E Wessman
Journal:  J Clin Microbiol       Date:  1978-02       Impact factor: 5.948

5.  The relationship between the O-antigenic lipopolysaccharides and serological specificity in strains of Pseudomonas aeruginosa of different O-serotypes.

Authors:  I R Chester; P M Meadow; T L Pitt
Journal:  J Gen Microbiol       Date:  1973-10

6.  Expression of two structurally distinct D-galactan O antigens in the lipopolysaccharide of Klebsiella pneumoniae serotype O1.

Authors:  C Whitfield; J C Richards; M B Perry; B R Clarke; L L MacLean
Journal:  J Bacteriol       Date:  1991-02       Impact factor: 3.490

Review 7.  Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides.

Authors:  J B Robbins; C Chu; R Schneerson
Journal:  Clin Infect Dis       Date:  1992-08       Impact factor: 9.079

8.  Antigenic relationships between the serotypes of Pasteurella haemolytica demonstrable by enzyme-linked immunosorbent assay (ELISA).

Authors:  C Burrells; H B Evans; A M Dawson
Journal:  Vet Microbiol       Date:  1983-04       Impact factor: 3.293

9.  Structure of the O-chain of the lipopolysaccharide of Pasteurella haemolytica serotype T3.

Authors:  R A Leitch; J C Richards
Journal:  Biochem Cell Biol       Date:  1988-10       Impact factor: 3.626

10.  Immunogenic properties of lipid A.

Authors:  C Galanos; M A Freudenberg; F Jay; D Nerkar; K Veleva; H Brade; W Strittmatter
Journal:  Rev Infect Dis       Date:  1984 Jul-Aug
View more
  7 in total

1.  Increase of glycocalyx and altered lectin agglutination profiles of Pasteurella haemolytica A1 after incubation in bovine subcutaneous tissue chambers in vivo or in ruminant serum in vitro.

Authors:  K Brogden; C Clarke
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

2.  Molecular analysis of the leukotoxin determinants from Pasteurella haemolytica serotypes 1 to 16.

Authors:  L L Burrows; E Olah-Winfield; R Y Lo
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

3.  Biochemical conditions for the production of polysialic acid by Pasteurella haemolytica A2.

Authors:  L Puente-Polledo; A Reglero; C González-Clemente; L B Rodríguez-Aparicio; M A Ferrero
Journal:  Glycoconj J       Date:  1998-09       Impact factor: 2.916

4.  Lipopolysaccharide complexes with Pasteurella haemolytica leukotoxin.

Authors:  J Li; K D Clinkenbeard
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

5.  Construction and characterization of an acapsular mutant of Mannheimia haemolytica A1.

Authors:  Linda J McKerral; Reggie Y C Lo
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

6.  Evolutionary genetics of Pasteurella haemolytica isolates recovered from cattle and sheep.

Authors:  R L Davies; S Arkinsaw; R K Selander
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

7.  Pathogenic Mannheimia haemolytica Invades Differentiated Bovine Airway Epithelial Cells.

Authors:  Daniel Cozens; Erin Sutherland; Miquel Lauder; Geraldine Taylor; Catherine C Berry; Robert L Davies
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.